Techno Medica (6678) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2025, was ¥4,104 million, a 0.3% decrease year-over-year due to lower domestic sales of blood collection tube preparation systems.

• Operating profit declined 12.6% year-over-year to ¥266 million, with net profit down 8.4% to ¥203 million.

• Overseas sales accounted for 17.0% of total revenue, down 0.1 points from the previous year.

• The company focused on value-added solutions for medical facilities and expanded self-monitoring products for general users.

Financial highlights

• Gross profit fell 5.9% year-over-year to ¥1,956 million, while SG&A expenses decreased 4.7% to ¥1,690 million.

• Ordinary profit was ¥294 million, down 1.4% year-over-year.

• EPS for the interim period was ¥29.31, compared to ¥32.06 in the prior year.

• Cash and equivalents at period-end were ¥8,808 million, down ¥253 million from the previous year-end.

Outlook and guidance

• Full-year revenue forecast remains unchanged at ¥10,600 million, with operating profit projected at ¥1,480 million and net profit at ¥1,100 million.

• Annual dividend forecast is ¥68 per share, unchanged from previous guidance.